Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.56 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307465 | 1.00 | CHRNA7 (0.56) | CHRNA7GPR183HPGDSPAK1NAAA | |
| SCHEMBL6311008 | 0.95 | CHRNA7 (0.49) | CHRNA7GPR183HPGDSPAK1NAAA | |
| SCHEMBL6305790 | 0.88 | CHRNA7 (0.58) | CHRNA7PAK1NAAAUSP30KMT2A | |
| SCHEMBL6305794 | 0.88 | CHRNA7 (0.58) | CHRNA7PAK1NAAAUSP30KMT2A | |
| SCHEMBL6303017 | 0.87 | CHRNA7 (0.66) | CHRNA7NAAAUSP30MEN1KMT2A | |
| SCHEMBL6303021 | 0.87 | CHRNA7 (0.66) | CHRNA7NAAAUSP30MEN1KMT2A | |
| SCHEMBL6303155 | 0.87 | CHRNA7 (0.66) | CHRNA7NAAAUSP30MMP2MMP13 | |
| SCHEMBL6303153 | 0.87 | CHRNA7 (0.66) | CHRNA7NAAAUSP30MMP2MMP13 | |
| SCHEMBL6311955 | 0.84 | CHRNA7 (0.69) | CHRNA7HPGDSMEN1KMT2A | |
| SCHEMBL6311947 | 0.84 | CHRNA7 (0.69) | CHRNA7HPGDSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | claimed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNA7 2937/4885GPR183 1237/4885HPGDS 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.